Efficacy and Safety of Sitagliptin/Metformin Fixed-Dose Combination (FDC) Compared to Glimepiride in Participants With Type 2 Diabetes Mellitus (MK-0431A-202)

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 292 participants.

Also called NCT00993187

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 292 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT00993187
Other papers using this trial's data
  • Efficacy and safety of sitagliptin/metformin fixed-dose combination compared with glimepiride in patients with type 2 diabetes: A multicenter randomized double-blind study Journal of diabetes, 2017-04 DOI, PubMed 27229178

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
Not reported
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT00993187. Randomized; double masking; primary purpose treatment. Start 2010-05-04 (actual); primary completion 2013-10-29 (actual). Results posted on 2014-09-15.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Efficacy and Safety of Sitagliptin/Metformin Fixed-Dose Combination (FDC) Compared to Glimepiride in Participants With Type 2 Diabetes Mellitus (MK-0431A-202)
Condition
Type 2 Diabetes Mellitus
Intervention (Drug)
Sitagliptin/Metformin FDC
Intervention (Drug)
Comparator: Glimepiride
Intervention (Drug)
Matching placebo to Sitagliptin/Metformin FDC
Intervention (Drug)
Matching placebo to glimepiride
Lead sponsor
Merck Sharp & Dohme LLC (class: industry)

Record details

Record id
cardio:ct-nct00993187
Content hash
7467eca3f0f6196019dad8b2c1f584a3e0d67d3083db62b3e53b8e3ed6bb2b57